Core Viewpoint - 康龙化成 is experiencing a slight increase in stock price and has a significant market capitalization, benefiting from various industry trends including digital transformation and AI integration in clinical services [1][2]. Company Overview - 康龙化成 (Beijing) New Drug Technology Co., Ltd. specializes in integrated drug research, development, and production services, covering the entire process from drug discovery to development [2][7]. - The company's main revenue sources include laboratory services (60.43%), CMC (small molecule CDMO) services (21.58%), clinical research services (14.58%), and other services [7]. Financial Performance - For the period from January to September 2025, 康龙化成 achieved a revenue of 10.086 billion yuan, representing a year-on-year growth of 14.38%, while the net profit attributable to shareholders decreased by 19.76% to 1.141 billion yuan [8]. - The company has distributed a total of 1.794 billion yuan in dividends since its A-share listing, with 1.007 billion yuan distributed over the past three years [9]. Market Position and Trends - 康龙化成 is positioned as a leader in the CRO (Contract Research Organization) sector, particularly in small molecule drug research services, and ranks second in drug discovery in China [2][3]. - The company is benefiting from the depreciation of the RMB, with overseas revenue accounting for 84.95% of total revenue [3]. Digital Transformation and AI Integration - 康龙化成 has made significant progress in digital and intelligent construction within its clinical services, establishing a "Digital Innovation Technology Department" to enhance efficiency through automation and machine learning [3]. - The acquisition of Shanghai Jiying is expected to further promote the company's digital transformation in clinical services, although it may face integration and management challenges [2][3].

Core Viewpoint - Suzhou Wangshan Wangshui Biopharmaceutical Co., Ltd. successfully listed on the Hong Kong Stock Exchange, raising approximately HKD 587 million, marking a significant milestone for the company and enhancing its international presence [1][3]. Group 1: Company Overview - Wangshan Wangshui, established in 2013, is a comprehensive biopharmaceutical company focused on discovering, developing, and commercializing innovative small molecule drugs, particularly in the fields of neuropsychiatry, reproductive health, and viral infections [6]. - The company has developed a competitive and diversified pipeline of innovative drug products, with two products in the commercialization stage, four in clinical stages, and three in preclinical stages [3][6]. Group 2: IPO Details - The IPO of Wangshan Wangshui was highly successful, with a subscription rate of 6,238.42 times, ranking second in the healthcare sector and fourth overall among new listings on the Hong Kong Stock Exchange in 2025 [3][5]. - Citic Securities acted as the sole sponsor and played a crucial role in the IPO process, demonstrating its expertise in the biopharmaceutical sector [1][4]. Group 3: Product Development - The product "Mindewei®" received conditional approval from the National Medical Products Administration of China in January 2023 and transitioned to regular approval in January 2025 for the treatment of mild to moderate COVID-19 [6]. - The product "TPN171," marketed as "Angweida®," was approved in July 2025 for the treatment of erectile dysfunction in men [6]. Group 4: Industry Impact - Citic Securities is committed to supporting the health industry and has deepened its involvement in the medical and health sector, leveraging its comprehensive service capabilities to empower the capitalization of Chinese innovative pharmaceutical companies [4][5].

Group 1: Report General Information - Report title: Fund Analysis Special Report (In - Depth) [1] - Report date: November 6, 2025 [1] Group 2: Hong Kong Stock Fund Performance and Scale Development Performance - **Return**: Among different types of Hong Kong stock funds, in the recent quarter, the return of Hong Kong - Stock Connect - Active funds was 20.11%, and that of Hong Kong - Stock QDII - Active funds was 22.43%. In the recent year, the return of Hong Kong - Stock QDII - Active funds reached 55.02%. In the recent 3 - year and 5 - year periods, different types of funds also showed various returns [13]. - **Maximum drawdown**: The maximum drawdown of Hong Kong - Stock Connect - Active funds in the recent quarter was - 4.57%, and that of Hong Kong - Stock QDII - ETF&Passive Index funds in the recent 5 - year period was - 54.98% [13]. - **Annualized Sharpe ratio**: The annualized Sharpe ratio of Hong Kong - Stock Connect - Active funds in the recent quarter was 3.87, and that of Hong Kong - Stock QDII - ETF&Passive Index funds in the recent 5 - year period was 0.11 [13]. Scale and Share - The report presents the scale development and share changes of different types of Hong Kong stock funds through relevant charts [17] New Fund Issuance - The new issuance situation of Hong Kong stock funds in each quarter is shown in the chart [21] Group 3: Hong Kong Stock Fund Positioning Characteristics Stock and Hong Kong Stock Positions - The distribution of stock positions and Hong Kong stock positions of Hong Kong stock funds in different periods is presented. For example, from 2024/12/31 to 2025/9/30, the proportion of different industries in the stock positions showed certain changes [29] Sector and Stock Allocation - **Sector allocation**: In 2025Q3, the top sectors in the heavy - position stocks of Hong Kong stock funds included Media (22.31%), Commerce and Retail (16.99%), and Pharmaceutical Biology (15.52%) [33]. - **Stock allocation**: The top 10 stocks in terms of market - value ratio in 2025Q3 included Alibaba - W (13.87%) and Tencent Holdings (13.00%). The report also shows the top 10 stocks for increased and decreased positions [35]. - **Number of heavy - position funds**: Tencent Holdings had the largest number of holding funds in 2025Q3 (192), and the report also shows the top 10 stocks for increased and decreased positions in terms of the number of holding funds [37]. - **Market - value distribution and concentration**: The market - value distribution and concentration of heavy - position stocks of Hong Kong stock funds are presented [42] Group 4: Hong Kong Stock Fund Company Analysis Fund Company Scale - The top 20 fund companies in terms of Hong Kong stock fund scale in 2025Q3 are listed. For example, E Fund had a scale of 155.06 billion yuan in 2025Q3, with a scale change of 79.91% compared to 2025Q2 [44]. Heavy - Position Industries and Stocks - **Heavy - position industries**: Different fund companies have different first, second, and third heavy - position industries. For example, E Fund's first heavy - position industry in 2025Q3 was Non - Banking Finance (29.53%), with a 14.61% change compared to the previous period [47]. - **Heavy - position stocks**: Each fund company has its own top heavy - position stocks. For example, E Fund's first heavy - position stock was Tencent Holdings (16.52%) [48]. Group 5: High - Performance Hong Kong Stock Fund Positioning Display and Quarterly Report Views Positioning Display - The report shows the heavy - position stocks of some high - performance actively managed Hong Kong stock funds in 25Q3, including their fund codes, names, types, 25Q3 returns, fund managers, total scales, and the proportion of the market value of holding stocks to the fund net value [51][52] Quarterly Report Views - Different high - performance funds have different investment strategies and views. For example, HuaAn Hong Kong - Shanghai - Shenzhen Connect Select A believes that the semiconductor, communication, and new - energy industries have contributed excess returns, and it has increased positions in Hong Kong stock Internet and A - share self - controllable industrial chains [53].

Group 1 - The STAR Market 50 Index increased by 2.8%, the STAR Growth Index rose by 2.3%, the STAR Composite Index went up by 2%, and the STAR 100 Index gained 1.7% as of the midday close, indicating strong market interest in related products [1] - The STAR Market 50 ETF (588080) attracted over 500 million yuan in the last five trading days, reflecting significant investor interest [1] Group 2 - The STAR Market 50 Index tracks the top 50 stocks on the STAR Market, characterized by large market capitalization and good liquidity, with over 65% of its composition in the semiconductor sector and nearly 80% combined in medical devices, software development, and photovoltaic equipment [3] - The STAR 100 ETF focuses on 100 stocks with medium market capitalization and good liquidity, emphasizing small and medium-sized innovative enterprises, with over 80% in electronics, pharmaceuticals, and power equipment sectors [4] - The STAR Composite Index ETF covers all securities in the STAR Market, focusing on core industries such as artificial intelligence, semiconductors, new energy, and innovative pharmaceuticals, encompassing all 17 primary industries listed on the STAR Market [6] - The STAR Growth 50 ETF tracks 50 stocks with high growth rates in revenue and net profit, with a significant representation from high-growth sectors like electronics and pharmaceuticals [6]

Core Viewpoint - The report from Huafu Securities indicates that China's innovative drug sector is experiencing a "quantitative change leading to qualitative change," with a positive outlook for the industry over the next 5-10 years driven by business development (BD) overseas, continuous data catalysts, and the ramp-up of new product sales [1] Group 1: Investment Recommendations - It is recommended to focus on Biopharma companies that have both BD expectations and commercial support for growth, as well as leading Pharma companies that are beginning to realize true innovation [1] - For Biotech and generic-to-innovative companies, attention should be given to those with potential blockbuster data or BD expectations that could act as catalysts [1] Group 2: Market Potential and Demand - The antidepressant market has significant potential, with over 350 million people affected globally, including more than 90 million in China, indicating a substantial disease burden [2] - The global antidepressant market is projected to reach approximately $17.11 billion by 2024, highlighting the vast market size [2] Group 3: Drug Development Challenges - Existing antidepressants have unmet needs in terms of efficacy and safety, with room for improvement in patient response rates [2] - Current drug development focuses on balancing "rapid onset" and "long-term safety," primarily through "monoamine deepening + multi-mechanism combination" strategies [2] Group 4: Industry Trends and Catalysts - The innovative drug sector is rebounding after a two-month adjustment, with a shift in focus from broad valuation recovery to the fundamental performance of companies [3] - Key industry catalysts include the start of medical insurance negotiations in November and upcoming industry conferences (ASH, ESMOASIA/IO) that may lead to data releases or clinical advancements [3]

Core Viewpoint - The biopharmaceutical sector on the STAR Market has shown mixed performance, with the STAR Biopharmaceutical Index declining by 0.60% as of November 6, 2025, while individual stocks exhibited varied movements, indicating a potential for structural recovery in the sector [1][4]. Group 1: Market Performance - The STAR Biopharmaceutical Index decreased by 0.60% as of November 6, 2025, with stocks like Huaheng Biological leading gains at 2.86%, while Yifang Biological experienced the largest decline [1]. - The Jiashi STAR Biopharmaceutical ETF recorded a turnover of 6.67% and a transaction volume of 21.39 million yuan, reaching a new high of 322 million yuan in scale, ranking first among comparable funds [3]. - The Jiashi STAR Biopharmaceutical ETF has seen a net inflow of 56.85 million yuan over the past four days, with a peak single-day net inflow of 16.85 million yuan [3]. Group 2: Fund Performance - As of November 5, 2025, the Jiashi STAR Biopharmaceutical ETF has achieved a one-year net value increase of 26.53%, with the highest monthly return since inception being 23.29% and the longest consecutive monthly gain lasting seven months [3]. - The average monthly return during the rising months of the Jiashi STAR Biopharmaceutical ETF is 7.85% [3]. Group 3: Industry Outlook - Recent adjustments in the pharmaceutical sector are attributed to a recovery in capital market financing and an increase in the scale of innovative drug exports, leading to a rebound in domestic innovative drug research and development [3]. - The outlook for the innovative drug sector remains focused on business development (BD) expectations, with BD activities typically accounting for about 40% of annual transactions in the fourth quarter [3]. - According to data, the top ten weighted stocks in the STAR Biopharmaceutical Index account for 49.74% of the index, indicating a concentration of investment in key players [4][6].

Core Viewpoint - The domestic ETF market has seen significant growth in 2025, with total scale exceeding 5.7 trillion yuan, driven by thematic ETFs in sectors like innovative pharmaceuticals, AI, chips, banking, and non-ferrous metals, contrasting with the focus on broad index ETFs in 2024 [2][4]. Market Performance - In the first ten months of 2025, the total scale of stock ETFs in the market increased by 836.8 billion yuan, marking a growth rate of 28.98% [4]. - Hua Bao Fund's stock ETFs grew by 60.80% to reach a management scale of 131.49 billion yuan, setting a new historical high [4][6]. - As of October 31, 2025, Hua Bao Fund's total ETF scale (including money market ETFs) surpassed 200 billion yuan, reaching 204.73 billion yuan, ranking it among the top 10 in the public fund industry [4][6]. Thematic ETFs - Thematic ETFs have become increasingly popular, with Hua Bao Fund's stock ETFs seeing a net inflow of 33.66 billion yuan in the first ten months of 2025, indicating strong market interest [11]. - The top five ETFs, referred to as the "Five Flowers," include the broker ETF (512000), financial technology ETF (159851), bank ETF (512800), Hong Kong internet ETF (513770), and chemical ETF (516020), all of which have attracted significant capital inflows [11][13]. Performance of Specific ETFs - The broker ETF (512000) has seen a net profit of 182.55 billion yuan from 49 listed brokers, with a year-on-year growth of 61.87% [11]. - The financial technology ETF (159851) has attracted 5.35 billion yuan in net inflows, while the bank ETF (512800) has seen inflows of 10.6 billion yuan [11]. - The innovative pharmaceutical ETF (520880) has shown a remarkable increase of 83.47% since the beginning of 2025, while the AI ETF (159363) and non-ferrous metal ETF (159876) have increased by 80.97% and 74.80%, respectively [22][24]. Growth of ETF Scale - The number of stock ETFs under Hua Bao Fund has expanded to 39, with a total scale exceeding 100 billion yuan for several ETFs, indicating a strong presence in the market [16][17]. - The bank ETF (512800) and financial technology ETF (159851) have both surpassed the 10 billion yuan mark, contributing to Hua Bao Fund's position in the "100 billion ETF club" [16][27].

Core Insights - The pharmaceutical sector showed signs of marginal recovery in Q3 2025, with a focus on academic conferences, policy changes, and business development catalysts expected in Q4 2025 [1][2] - The Hong Kong pharmaceutical market experienced a pullback in October due to sentiment decline and profit-taking, but the underlying fundamentals remain strong, with an anticipated stabilization in investment sentiment starting November [2] Market Performance - The Hang Seng Healthcare Index fell by 1.3% this week, outperforming the broader market, with traditional Chinese medicine, biopharmaceuticals, and distribution sectors showing better performance [1] - Domestic institutions increased their positions in high-value innovative drug targets, medical device companies, and service-oriented firms, particularly those benefiting from interest rate cuts and downstream demand recovery [1] Investment Recommendations - Focus on innovative drugs such as Sanofi and Deqi Pharmaceuticals, which have rich short-term catalysts and valuations that do not yet reflect the value of core products; companies like Xiansheng Pharmaceuticals, Hutchison China MediTech, and Legend Biotech are significantly undervalued with clear long-term growth logic [2] - In the CXO sector, leading firms benefiting from high downstream demand and marginal financing recovery are recommended, such as WuXi AppTec [2]

Core Insights - Baili Tianheng's stock price decreased by 2.10% on November 6, trading at 357.55 CNY per share, with a total market capitalization of 147.623 billion CNY [1] - The company has seen a year-to-date stock price increase of 86.49%, with a recent 5-day increase of 6.26% and a 20-day decrease of 2.44% [1] - For the first nine months of 2025, Baili Tianheng reported a revenue of 2.066 billion CNY, a year-on-year decrease of 63.52%, and a net profit loss of 495 million CNY, a decrease of 112.16% [2] Company Overview - Baili Tianheng Pharmaceutical Co., Ltd. was established on August 17, 2006, and listed on January 6, 2023 [1] - The company is located in Chengdu, Sichuan Province, and its main business involves the research, production, and sales of pharmaceuticals [1] - The revenue composition indicates that 99.57% of income is recognized at a specific point in time, while 0.43% is recognized over a period [1] Shareholder and Institutional Holdings - As of September 30, 2025, the number of shareholders increased by 25.08% to 5,979, while the average circulating shares per person decreased by 20.05% to 17,208 shares [2] - The top ten circulating shareholders include various funds, with notable reductions in holdings from several major shareholders [3] - New entrants among the top shareholders include Yongying Medical Innovation Mixed Fund A and Huatai-PB CSI 300 ETF [3]

Core Viewpoint - Zai Lab's stock price has shown significant volatility, with a year-to-date increase of 59.94% but a recent decline in the last 20 and 60 days, indicating potential market fluctuations and investor sentiment changes [1][2]. Group 1: Stock Performance - As of November 6, Zai Lab's stock price was 99.66 CNY per share, with a market capitalization of 26.381 billion CNY [1]. - The stock has experienced a 59.94% increase year-to-date, an 11.43% increase over the last five trading days, a 6.52% decrease over the last 20 days, and a 10.83% decrease over the last 60 days [1]. - The company has appeared on the "龙虎榜" (a trading board for stocks with significant trading volume) once this year, with a net buy of 187 million CNY on October 31 [1]. Group 2: Financial Performance - For the period from January to September 2025, Zai Lab reported a revenue of 593 million CNY, representing a year-on-year growth of 54.49% [2]. - The company recorded a net profit attributable to shareholders of -93.4162 million CNY, showing a year-on-year increase of 4.58% despite being negative [2]. Group 3: Shareholder Information - As of September 30, 2025, Zai Lab had 8,809 shareholders, a slight increase of 0.16% from the previous period [2]. - The average number of circulating shares per shareholder was 30,049, which decreased by 0.16% compared to the previous period [2]. - Notable institutional shareholders include 中欧医疗健康混合A and 工银前沿医疗股票A, with varying changes in their holdings [2].